Incidence and predictors of idiopathic pulmonary fibrosis complicating Type 2 diabetes: the Fremantle Diabetes Study Phase I

2021 ◽  
Vol 51 (2) ◽  
pp. 276-279
Author(s):  
Vidya Navaratnam ◽  
Timothy M. E. Davis ◽  
Richard Hubbard ◽  
Wendy A. Davis
Keyword(s):  
Type 2 Diabetes ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Phase I ◽  
Study Phase

scholarly journals Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I

Diabetologia ◽  
2016 ◽  
Vol 60 (1) ◽  
pp. 89-97 ◽  
Author(s):  
Wendy A. Davis ◽  
Renate R. Zilkens ◽  
Sergio E. Starkstein ◽  
Timothy M. E. Davis ◽  
David G. Bruce
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Phase I ◽  
Study Phase ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Dementia Onset

scholarly journals Diabetic Pneumopathy–A New Diabetes-Associated Complication: Mechanisms, Consequences and Treatment Considerations

2021 ◽  
Vol 12 ◽  
Author(s):  
Stefan Kopf ◽  
Varun Kumar ◽  
Zoltan Kender ◽  
Zhe Han ◽  
Thomas Fleming ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dna Damage ◽  
Dna Repair ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Diabetic Patients ◽  
Dna Damage Signaling ◽  
Patients With Diabetes ◽  
Treatment Considerations

Patients with diabetes are over-represented among the total cases reported with “idiopathic” pulmonary fibrosis (IPF). This raises the question, whether this is an association only or whether diabetes itself can cause pulmonary fibrosis. Recent studies in mouse models of type 1 and type 2 diabetes demonstrated that diabetes causes pulmonary fibrosis. Both types of diabetes trigger a cascade, starting with increased DNA damage, an impaired DNA repair, and leading to persistent DNA damage signaling. This response, in turn, induces senescence, a senescence-associated-secretory phenotype (SASP), marked by the release of pro-inflammatory cytokines and growth factors, finally resulting in fibrosis. Restoring DNA repair drives fibrosis into remission, thus proving causality. These data can be translated clinically to patients with type 2 diabetes, characterized by long-term diabetes and albuminuria. Hence there are several arguments, to substitute the term “idiopathic” pulmonary fibrosis (IPF) in patients with diabetes (and exclusion of other causes of lung diseases) by the term “diabetes-induced pulmonary fibrosis” (DiPF). However, future studies are required to establish this term and to study whether patients with diabetes respond to the established therapies similar to non-diabetic patients.

scholarly journals The TELE-DD project on treatment nonadherence in the population with type 2 diabetes and comorbid depression

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Juan Francisco Roy ◽  
María Luisa Lozano del Hoyo ◽  
Fernando Urcola-Pardo ◽  
Alicia Monreal-Bartolomé ◽  
Diana Cecilia Gracia Ruiz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Type 2 Diabetes ◽  
Phase I ◽  
Clinical Depression ◽  
Point Prevalence ◽  
Diabetic Patients ◽  
Comorbid Depression ◽  
Shared Risk

AbstractDiabetic patients have increased depression rates, diminished quality of life, and higher death rates due to depression comorbidity or diabetes complications. Treatment adherence (TA) and the maintenance of an adequate and competent self-care are crucial factors to reach optimal glycaemic control and stable quality of life in these patients. In this report, we present the baseline population analyses in phase I of the TELE-DD project, a three-phased population-based study in 23 Health Centres from the Aragonian Health Service Sector II in Zaragoza, Spain. The objectives of the present report are: (1) to determine the point prevalence of T2D and clinical depression comorbidity and treatment nonadherence; (2) to test if HbA1c and LDL-C, as primary DM outcomes, are related to TA in this population; and (3) to test if these DM primary outcomes are associated with TA independently of shared risk factors for DM and depression, and patients’ health behaviours. A population of 7,271 patients with type-2 diabetes and comorbid clinical depression was investigated for inclusion. Individuals with confirmed diagnoses and drug treatment for both illnesses (n = 3340) were included in the current phase I. A point prevalence of 1.9% was found for the T2D-depression comorbidity. The prevalence of patients nonadherent to treatment for these diseases was 35.4%. Multivariate analyses confirmed that lower diabetes duration, increased yearly PCS visits, HbA1c and LDL-C levels were independently related to treatment nonadherence. These findings informed the development of a telephonic monitoring platform for treatment of nonadherence for people with diabetes and comorbid depression and further trial, cost-effectiveness, and prognostic studies (phases II and III).

scholarly journals Influence of Renin-Angiotensin System Inhibitors on Lower Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

2020 ◽  
Author(s):  
Timothy M E Davis ◽  
Wendy A Davis
Keyword(s):  
Type 2 Diabetes ◽  
Respiratory Tract ◽  
Phase Ii ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Study Phase ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections

Objective:<b> </b>To determine whether<b> </b>angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) protect against lower respiratory tract infections complicating type 2 diabetes. <p>Research design and methods:<b> </b>Of 1,732 participants with diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011, 1,482 had confirmed type 2 diabetes (mean age of 65.8 years, 51.6% were males, median diabetes duration 9.0 years). All were followed for hospitalizations for/with, or deaths from, pneumonia/influenza ascertained from validated administrative data linkage from study entry to end-2016. Cox and competing risk regression were used to identify independent predictors of this outcome.</p> <p>Results:<b> </b>Two-thirds of participants (n=982) were taking an ACEi and/or ARB at study entry (498 (33.6%) ACEi, 408 (27.5%) ARB, 76 (5.1%) both).<b> </b>During 9,511 person-years of follow-up (mean 6.4±2.0 years), 174 participants had incident pneumonia/influenza (156 hospitalizations, 18 deaths without hospitalization). In Cox regression analysis, baseline ACEi/ARB use was independently associated with a reduced risk of incident pneumonia/influenza (cause-specific hazard ratio (HR) (95% confidence interval) 0.64 (0.45, 0.89), <i>P</i>=0.008). Allowing for the competing risk of death did not change this finding (subdistribution HR 0.67 (0.48, 0.95), <i>P</i>=0.024), and similar reductions were seen for ACEi, ARB alone, and ACEi/ARB combination therapy. There was no significant change in use of ACEi/ARB during follow-up (interaction with ln(time), <i>P</i>=0.70). Other significant predictors of incident pneumonia/influenza were previously reported, clinically plausible variables.</p> <p>Conclusions:<b> </b>ACEi/ARB reduce the risk of pneumonia/influenza in community-based people with type 2 diabetes.<b><br> </b></p>

Sign in / Sign up

Export Citation Format

Share Document